Summary
Cristal Therapeutics (CT) develops the next generation of nanomedicines to treat cancer. Cancer remains one the leading causes of death worldwide, and current treatment options are insufficient, in part due to the tumour heterogeneity between patients. CT has developed state-of-the-art nanoparticles (CriPec®) to target a drug of choice more selectively to the tumour site(s). The superior therapeutic performance of this approach has already been demonstrated preclinically for CT’ lead product CriPec® docetaxel and a promising clinical phase I trial is finalizing, providing a significantly increased pharmacokinetic and safety profile. CT already observed activity in patients and much reduced neutropenia and alopecia.
In INTACT, CT will perform phase II clinical trials in ovarian and bladder cancer to evaluate the therapeutic efficacy of CriPec® docetaxel. Furthermore, CriPec® docetaxel will be decorated with a PET tracer (89Zr), which enables oncologists to visualize CriPec® biodistribution in real-time. Tumour uptake will be correlated with therapeutic responses and result in parameters for future patient selection.
This approach turns the drug into a personalized medicine whereby only those patients that exhibit enhanced tumour-targeting will be treated. This personalisation assures maximum efficacy in selected patients, avoids exposing patients to inappropriate drugs and adverse effects, and allows patients with limited tumour targeting to receive other more appropriate treatment.
CT will use INTACT to close the gap from lab to market and facilitate a licensing deal for CriPec® docetaxel, projected to generate revenues exceeding >€100M in 2024. More importantly, INTACT will validate the CriPec® nanomedicine platform, boost product development for other diseases through licensing deals, and provide a growth of 10FTE by 2022. Success in INTACT will truly launch Cristal Therapeutics’ business.
In INTACT, CT will perform phase II clinical trials in ovarian and bladder cancer to evaluate the therapeutic efficacy of CriPec® docetaxel. Furthermore, CriPec® docetaxel will be decorated with a PET tracer (89Zr), which enables oncologists to visualize CriPec® biodistribution in real-time. Tumour uptake will be correlated with therapeutic responses and result in parameters for future patient selection.
This approach turns the drug into a personalized medicine whereby only those patients that exhibit enhanced tumour-targeting will be treated. This personalisation assures maximum efficacy in selected patients, avoids exposing patients to inappropriate drugs and adverse effects, and allows patients with limited tumour targeting to receive other more appropriate treatment.
CT will use INTACT to close the gap from lab to market and facilitate a licensing deal for CriPec® docetaxel, projected to generate revenues exceeding >€100M in 2024. More importantly, INTACT will validate the CriPec® nanomedicine platform, boost product development for other diseases through licensing deals, and provide a growth of 10FTE by 2022. Success in INTACT will truly launch Cristal Therapeutics’ business.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/784127 |
| Start date: | 01-08-2017 |
| End date: | 30-06-2020 |
| Total budget - Public funding: | 5 818 516,50 Euro - 2 499 999,00 Euro |
Cordis data
Original description
Cristal Therapeutics (CT) develops the next generation of nanomedicines to treat cancer. Cancer remains one the leading causes of death worldwide, and current treatment options are insufficient, in part due to the tumour heterogeneity between patients. CT has developed state-of-the-art nanoparticles (CriPec®) to target a drug of choice more selectively to the tumour site(s). The superior therapeutic performance of this approach has already been demonstrated preclinically for CT’ lead product CriPec® docetaxel and a promising clinical phase I trial is finalizing, providing a significantly increased pharmacokinetic and safety profile. CT already observed activity in patients and much reduced neutropenia and alopecia.In INTACT, CT will perform phase II clinical trials in ovarian and bladder cancer to evaluate the therapeutic efficacy of CriPec® docetaxel. Furthermore, CriPec® docetaxel will be decorated with a PET tracer (89Zr), which enables oncologists to visualize CriPec® biodistribution in real-time. Tumour uptake will be correlated with therapeutic responses and result in parameters for future patient selection.
This approach turns the drug into a personalized medicine whereby only those patients that exhibit enhanced tumour-targeting will be treated. This personalisation assures maximum efficacy in selected patients, avoids exposing patients to inappropriate drugs and adverse effects, and allows patients with limited tumour targeting to receive other more appropriate treatment.
CT will use INTACT to close the gap from lab to market and facilitate a licensing deal for CriPec® docetaxel, projected to generate revenues exceeding >€100M in 2024. More importantly, INTACT will validate the CriPec® nanomedicine platform, boost product development for other diseases through licensing deals, and provide a growth of 10FTE by 2022. Success in INTACT will truly launch Cristal Therapeutics’ business.
Status
CLOSEDCall topic
SMEInst-03-2016-2017Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
H2020-EU.2.1.4. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
